相关实验视频

Updated: Jan 13, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

68Ga-PSMA-11 PET/CT与传统成像用于对转移性割抵抗性前列腺癌的反应评估:单中心前性研究

Komal Preet¹, Ashwani Sood¹, Swayamjeet Satapathy^1,2

¹Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, Punjab.

Clinical nuclear medicine

|January 7, 2026

概括

前列腺癌工作组3 (PCWG3) 标准是评估转移性割抵抗性前列腺癌 (mCRPC) 治疗反应最有效的. 然而,RECIP-1.0在不接受雄激素受体通路抑制剂 (ARPI) 的患者中显示出更好的预后价值.

科学领域:

核医学就是核医学.
在瘤学瘤学.
放射学放射学是一门学科.

背景情况:

准确的反应评估对于接受多种治疗的转移性割抵抗性前列腺癌 (mCRPC) 患者至关重要.
基于RECIST-1.1的常规前列腺癌工作组3 (PCWG3) 标准是目前的响应评估标准.
68Ga-PSMA-11-PET/CT在前列腺癌分期方面表现有前途,但其在反应评估中的作用需要前性验证.

研究的目的:

在mCRPC患者中对PCWG3标准进行前性评估68Ga-PSMA-11-PET/CT基础的反应标准 (RECIP-1.0,PPP,aPERCIST).
将这些新标准的性能与已建立的PCWG3标准进行比较.

主要方法:

对mCRPC患者开始使用taxane,ARPI或177Lu-PSMA-617治疗的前性评估.
68Ga-PSMA-11-PET/CT和常规成像 (CECT,骨光学) 在基线和每12周进行一次.
使用PCWG3,RECIP-1.0,PPP和aPERCIST标准进行了反应评估.

主要成果:

包括34名mCRPC患者. 在12周的非进展率有所不同:PCWG3 (23.5%),aPERCIST (8.8%),PPP (17.6%) 和RECIP-1.0 (23.5%).
RECIP-1.0显示了最高的读者间一致性 (κ=0.84).
PCWG3非进展与显著改善的整体存活率 (OS) 相关联 (P=0.02). 无进展生存率 (rPFS) 显示了最高的C指数为OS (C=0.72),其次是RECIP-rPFS (C=0.71). 在非ARPI患者中,RECIP-rPFS优于非ARPI患者 (C=0.76),而PCWG3-rPFS在ARPI患者中更好 (C=0.75).

结论:

对于整体反应评估和用ARPI治疗的患者,PCWG3标准仍然是最有效的.
对于不接受ARPI的患者来说,RECIP-1.0的预后价值更高.
需要进行更大规模的研究来证实这些发现,并验证RECIP-1.0在特定mCRPC子组中的实用性.

关键词:

68 PSMA-11 PSMA-11 68 PSMA-11 68 PSMA-11 68 PSMA-11 68 PSMA-11 68 PSMA-11 68 PSMA-11 68 PSMA-11 68 PSMA-11 68 PSMA-11 68 PSMA-11 定子发射断层扫描计算机断层扫描计算机断层扫描没有进展的生存率.前列腺前列腺前列腺前列腺特异抗原前列腺特异抗原.在固体瘤中响应评估标准.

更多相关视频

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

相关概念视频

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...